Legato Capital Management’s Vaxcyte PCVX Stock Holding History

Legato Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,823	Closed	-$409K	–	604
2025 Q1	$409K	Buy	10,823 +1,818	+20%	+$145K	0.06%	452
2024 Q4	$737K	Sell	9,005 -2,627	-23%	-$261K	0.1%	371
2024 Q3	$1.33M	Buy	11,632 +613	+6%	+$55.2K	0.16%	218
2024 Q2	$832K	Buy	11,019 +3,010	+38%	+$205K	0.11%	307
2024 Q1	$547K	Sell	8,009 -4,187	-34%	-$290K	0.07%	422
2023 Q4	$766K	Buy	12,196 +1,498	+14%	+$77.8K	0.1%	324
2023 Q3	$545K	Sell	10,698 -9,210	-46%	-$454K	0.08%	381
2023 Q2	$994K	Buy	19,908 +13,383	+205%	+$634K	0.13%	262
2023 Q1	$245K	Buy	6,525 +2,334	+56%	+$99K	0.04%	429
2022 Q4	$201K	Buy	+4,191	New	+$164K	0.04%	453

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Legato Capital Management's PCVX Position: Q2 2025 in Review

Legato Capital Management sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 10,823 shares — an estimated $409K sold.

Legato Capital Management first reported a position in PCVX in Q4 2022 and held it in 10 quarters. The position peaked at $1.33M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Legato Capital Management reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Legato Capital Management sold 10,823 Vaxcyte shares in Q2 2025, an estimated $409K.
Legato Capital Management first reported a position in Vaxcyte in Q4 2022 and held it in 10 quarters.
Legato Capital Management's Vaxcyte position peaked at $1.33M in Q3 2024.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Legato Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.